A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to Osimertinib

Sakil Bhuiyan; Raheel S Siddiqui; Milana Zirkiyeva; Mariam Agladze; Tayyaba Bashir

doi:10.7759/cureus.15136

A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to Osimertinib

Cureus. 2021 May 20;13(5):e15136. doi: 10.7759/cureus.15136.

Authors

Sakil Bhuiyan¹, Raheel S Siddiqui¹, Milana Zirkiyeva¹, Mariam Agladze¹, Tayyaba Bashir²

Affiliations

¹ Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York City, USA.
² Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York City, USA.

Abstract

Small cell lung cancer (SCLC) accounts for less than 15% of the cases of lung cancer. Epidermal growth factor receptor (EGFR) mutations are rarely reported in association with SCLC. EGFR tyrosine kinase inhibitors (TKI) are approved as the first-line therapy for metastatic non-small cell lung cancer (NSCLC). The clinical effect of EGFR mutations and its response to osimertinib are unknown in SCLC. We report a case of EGFR-positive metastatic SCLC in a 63-year-old female who was treated with the third-generation TKI, osimertinib.

Keywords: egfr; nsclc; osimertinib; sclc; tki.

Publication types

Case Reports